Nov. 20 2025, Published 4:20 p.m. ET Disturbing photos of the cast of Wicked have sparked major health concerns and fueled accusations of “competitive anorexia” running rampant on the hit film’s set, RadarOnline.com can reveal. While the cast has been busy promoting Wicked: For Good, which hits theaters on November 21, fans have struggled to buy into the excitement for the sequel due to stars Ariana Grande, Cynthia Erivo, and Michelle Yeoh’s “sickly” appearances. Fans Raise Concerns About ‘Wicked’ Stars’ Weight Fans took to social media to share their concerns about Grande, Erivo, and Yeoh’s health while highlighting their weight loss in dramatic before-and-after photos. Commenters said the Wicked cast looked “emaciated” and pointed to their protruding bones and gaunt faces as alleged evidence something is wrong. “Guys, there’s no way to find this normal!” an X user wrote alongside a before-and-after photo of Yeoh. “Look at how Michelle was before that diabolical movie and look at how she is now (oh my god).” Another X user said the actresses reminded them of how their “dying grandma” looked when she “lost the ability to eat because of her ALS,” adding, “These people genuinely need help, they look like skeletons.” “Yeah, it’s honestly very concerning that the three female leads all had very healthy, strong figures before Wicked, and now all of them look like they weigh less than 100 pounds each… Like what is happening on those sets…” one user chimed in. “The cast of Wicked looks emaciated, and it’s very concerning. I hope someone steps in,” a second person wrote. “You can see their bones pushing against their skin. It looks really worrying, and them being put on a red carpet and stylized and everyone acting like it’s fine is freaking me out.” ‘Ally McBeal’ Comparisons Many comments echoed the sentiment about how the Wicked cast reminded them of tales from “toxic” shows and films in the 1990s and early aughts, particularly claims about hit TV show Ally McBeal. While promoting her 2010 memoir Unbearable Lightness, Portia de Rossi famously confessed her eating disorder skyrocketed while starring on Ally McBeal. In her book, she revealed her weight dropped to a shocking 82 pounds, prompting the beginning stages of organ failure. Later, her co-stars Courtney Thorne Smith and Calista Flockhart opened up on the pressure they felt to be skinny and extreme diets. Some suggested a similar confession about Wicked would surface in the future. “I feel like in 10 years we’re going to find out there was something insanely sinister going on on the set of Wicked,” one person said. “I haven’t seen a single cast member who looks like they have gotten healthier or happier through the course of filming.” Although some attempted to defend the cast and accuse critics of body shaming, they were quickly shut down as users overwhelmingly branded the actresses’ transformations “not normal.” “Call me crazy, but I don’t think it’s body shaming to genuinely wonder what’s going on and if they’re all ok,” an X user remarked as another added, “I’m so sick of people pretending that pointing out a dangerous trend is body shaming.”
https://radaronline.com/p/wicked-ariana-grande-cynthia-erivo-health-concerns-weight-loss/
Category Archives: healthcare
JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year, and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.
At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040, there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000. Do the math. According to Musk, this technology could be worth $250 trillion by 2040.
Put another way, that’s roughly equal to:
– 175 Teslas
– 107 Amazons
– 140 Metas
– 84 Googles
– 65 Microsofts
– 55 Nvidias
And here’s the wild part: this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy. It’s a leap so massive it could reshape how businesses, governments, and consumers operate worldwide.
Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.
—
### How Could Anything Be Worth That Much?
The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates. This breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.
What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution. In fact, Verge argues this company’s supercheap AI technology should concern rivals.
Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves:
– **Bill Gates** sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
– **Larry Ellison**, through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
– **Warren Buffett**, not known for tech hype, says this breakthrough could have a ‘hugely beneficial social impact.’
When billionaires from Silicon Valley to Wall Street line up behind the same idea, you know it’s worth paying attention to.
—
### Beyond Tesla, Nvidia, Alphabet, and Microsoft
Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere. The real story isn’t Nvidia; it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.
Judging by what I’m hearing from Silicon Valley insiders and Wall Street veterans, this prediction might not be bold at all: a few years from now, you’ll wish you’d owned this stock.
—
### Discover the Breakthrough Opportunity Now
The best part? You can discover everything about this company and its groundbreaking technology right now.
I’ve compiled everything you need to know about this breakthrough company in a detailed, members-only report. Trust me—you’ll want to read this before putting another dollar into any tech stock.
For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights—that’s less than a single fast food meal!
Here’s why this is a deal you can’t afford to pass up:
– **Access to our Detailed Report on this Game-Changing AI Stock:** Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
– **11 New Issues of Our Premium Readership Newsletter:** You will receive 11 new issues and at least one new stock pick per month, handpicked by our research director, Dr. Inan Dogan.
– **One Free Upcoming Issue of Our 70+ Page Quarterly Newsletter:** A value of $149.
– **Bonus Reports:** Premium access to members-only fund manager video interviews.
– **Ad-Free Browsing:** Enjoy a year of investment research free from distracting banner and pop-up ads.
– **30-Day Money-Back Guarantee:** If you’re not absolutely satisfied, we’ll provide a full refund within 30 days, no questions asked.
Space is limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away.
—
### Here’s What to Do Next:
1. Head over to our website and subscribe for just $9.99 a month.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
No worries about auto-renewals! Our 30-day money-back guarantee applies whether you’re joining us for the first time or renewing your subscription a month later.
—
### The Energy Behind AI’s Explosion
Artificial intelligence is the greatest investment opportunity of our lifetime. AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy.
In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future.
But there’s one urgent question few are asking: **Where will all of that energy come from?**
AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city—and it’s about to get worse.
Even Sam Altman, founder of OpenAI, issued a stark warning:
*“The future of AI depends on an energy breakthrough.”*
Elon Musk was even more blunt:
*“AI will run out of electricity by next year.”*
As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.
And that’s where the real opportunity lies.
—
### The “Toll Booth” Operator of the AI Energy Boom
One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play.
It’s not a chipmaker. It’s not a cloud platform.
But it might be the most important AI stock in the U.S. It owns critical energy infrastructure assets positioned to feed the coming AI energy spike.
As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.
It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy. It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine. Trump has made it clear: Europe and U.S. allies must buy American LNG. And our company sits in the toll booth—collecting fees on every drop exported.
But that’s not all. As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.
**AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.**
—
### Why Wall Street Is Starting to Notice
While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.
AI needs energy.
Energy needs infrastructure.
And infrastructure needs a builder with experience, scale, and execution.
This company has its finger in every pie—and Wall Street is just starting to notice.
Unlike most energy and utility firms buried under mountains of debt, this company is completely debt-free. In fact, it’s sitting on a war chest of cash equal to nearly one-third of its entire market cap. It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines—without paying a premium.
—
### The Hedge Fund Secret That’s Starting to Leak Out
This stock is so off-the-radar and absurdly undervalued that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.
They’re sharing it quietly, away from cameras, to rooms full of ultra-wealthy clients.
Why?
Because excluding cash and investments, this company is trading at less than 7 times earnings. And that’s for a business tied to:
– The AI infrastructure supercycle
– The onshoring boom driven by Trump-era tariffs
– A surge in U.S. LNG exports
– A unique footprint in nuclear energy—the future of clean, reliable power
You simply won’t find another AI and energy stock this cheap with this much upside.
This isn’t a hype stock. It’s not riding on hope. It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.
This is your chance to get in before the rockets take off!
—
### Disruption Is the New Name of the Game
Let’s face it: complacency breeds stagnation. AI is the ultimate disruptor, shaking the foundations of traditional industries. The companies that embrace AI will thrive while the dinosaurs clinging to outdated methods are left behind.
As an investor, you want to be on the side of the winners—and AI is the winning ticket.
—
### The Talent Pool Is Overflowing
The world’s brightest minds are flocking to AI. From computer scientists to mathematicians, the next generation of innovators is pouring energy and talent into this field.
This influx guarantees a constant stream of groundbreaking ideas and rapid advancements.
By investing in AI, you’re essentially backing the future.
—
### The Future Is Powered by Artificial Intelligence
The time to invest is NOW.
Don’t be a spectator in this technological revolution. Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.
This isn’t just about making money—it’s about being part of the future. So, buckle up and get ready for the ride of your investment life!
—
### Act Now and Unlock Potential 100+% Returns Within 12 to 24 Months
We’re now offering month-to-month subscriptions with no commitments. For just $9.99 per month, you can unlock our in-depth investment research and exclusive insights—that’s less than a single fast food meal!
Here’s what you get with this exclusive offer:
– Access to our detailed report on our AI, tariffs, and nuclear energy stock with 100+% potential upside within 12 to 24 months
– BONUS REPORT on our #1 AI-Robotics stock with 10,000% upside potential: an in-depth look at groundbreaking technology and massive growth potential
– One new issue of our Premium Readership Newsletter each month, including at least one new stock pick handpicked by research director Dr. Inan Dogan
– One free upcoming issue of our 70+ page quarterly newsletter (a $149 value)
– Premium access to members-only fund manager video interviews
– Ad-free browsing to focus on uncovering the next big opportunity
– Lifetime price guarantee: your renewal rate remains the same as long as your subscription is active
– 30-day money-back guarantee: full refund within 30 days, no questions asked
—
### Space Is Limited!
Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away.
Here’s what to do next:
1. Head over to our website and subscribe for just $9.99 per month.
2. Enjoy ad-free browsing, exclusive access to in-depth reports on the Trump tariff and nuclear energy company, the revolutionary AI-robotics company, plus ongoing issues of our Premium Readership Newsletter.
3. Sit back and relax, knowing you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future.
No worries about auto-renewals! Our 30-day money-back guarantee applies whether you’re joining for the first time or renewing your subscription a month later.
—
**Artificial intelligence is redesigning our world. The investment opportunity of a lifetime is here. Are you ready to seize it?**
https://www.insidermonkey.com/blog/jpmorgan-and-ubs-raise-pt-for-teva-pharmaceutical-teva-1630201/
New WakeMed health campus aims to transform mental health care
WakeMed is preparing to break ground on a new mental health campus in Garner. This development marks a significant step forward in expanding and improving behavioral health care services in the region.
Several physicians have shared with WRAL that these changes are expected to help transform the way behavioral health care is delivered. The new campus aims to provide enhanced resources and support for individuals facing mental health challenges.
Reporter: Grace Hayba
Web Editor: Sydney Ross
https://www.wral.com/video/new-wakemed-health-campus-aims-to-transform-mental-health-care/22207299/
WHO warns of global rise in antibiotic-resistant infections in hospitals
**WHO Warns of Global Rise in Antibiotic-Resistant Infections in Hospitals**
*By Snehil Singh | Oct 13, 2025, 04:11 PM*
The World Health Organization (WHO) has issued a stark warning about the rising prevalence of antibiotic-resistant infections in hospitals worldwide. According to data gathered from over 23 million bacterial infections across 104 countries, one in six laboratory-confirmed bacterial infections was resistant to antibiotic treatments in 2023.
### Alarming Loss of Antibiotic Effectiveness
Between 2018 and 2023, more than 40% of antibiotics lost their effectiveness against common infections affecting the blood, gut, urinary tract, and sexually transmitted diseases. This growing resistance threatens the success of treatments and puts patients’ lives at risk globally.
### Regional Disparities and Impact
The problem is most severe in low- and middle-income countries where healthcare systems tend to be weaker. Dr. Yvan Hutin, director of the WHO’s Department of Antimicrobial Resistance, described the findings as “deeply concerning,” emphasizing that “we are running out of treatment options and we are putting lives at risk.”
In particular, antibiotic resistance was found in:
– One in three bacterial infections in Southeast Asia and the Eastern Mediterranean regions.
– One in five bacterial infections in Africa.
Antimicrobial resistance (AMR) occurs when bacteria evolve to withstand drugs designed to kill them, making infections harder to treat.
### The Growing Toll of Drug-Resistant Infections
In 2021 alone, bacterial infections caused 7.7 million deaths worldwide. Of these, 4.71 million were linked to drug resistance, and 1.14 million were directly attributable to antibiotic-resistant infections.
### Treatment Challenges: The Threat of Gram-Negative Bacteria
The WHO report highlights particular concern about gram-negative bacteria such as *Escherichia coli* and *Klebsiella pneumoniae*, which are commonly responsible for severe infections leading to sepsis, organ failure, and death.
Dr. Hutin noted that 40% of *E. coli* and more than 55% of *K. pneumoniae* strains are now resistant to third-generation cephalosporins—the preferred first-line treatment for these infections. In the African region, resistance in these bacteria often exceeds 70%, posing significant treatment challenges.
### Urgent Calls for Action
Experts warn that if unchecked, antimicrobial resistance could reach a critical tipping point. Dr. Manica Balasegaram from the Global Antibiotic Research and Development Partnership projects that deaths caused by drug-resistant infections could rise sharply by 70% by 2050.
To combat this growing threat, Professor Sanjib Bhakta of University College London advocates for tailored global action, which includes:
– Strengthening surveillance of antibiotic resistance.
– Ensuring equitable access to narrow-spectrum antibiotics.
– Investing in research to develop novel therapies against drug-resistant bacteria.
The WHO’s alarming report underscores the urgent need for coordinated international efforts to address antibiotic resistance and safeguard the future of effective infection treatment worldwide.
https://www.newsbytesapp.com/news/world/sharp-rise-in-antibiotic-resistant-infections-in-hospitals-globally-says-who/story
Cancer treatment in India is about to become cheaper
**Cancer Treatment in India Set to Become Cheaper with New Nuclear Reactor**
*By Dwaipayan Roy | Oct 12, 2025, 05:20 PM*
The Department of Atomic Energy (DAE) is planning to build a dedicated nuclear reactor in Visakhapatnam aimed at producing medical isotopes primarily for cancer treatment. This significant initiative is designed to boost India’s self-sufficiency in radioisotope production and make cancer treatment more affordable for patients across the country.
A senior official from the Bhabha Atomic Research Centre (BARC) confirmed that the project is underway and is expected to take four to five years to complete under a Public-Private Partnership (PPP) model.
**Dual-Purpose Reactor to Serve Domestic and Export Markets**
The proposed reactor in Visakhapatnam will fulfill domestic demands for medical isotopes and also have the capacity to cater to international markets through exports. The project has already received government approval, with funding currently awaited.
Under this PPP initiative, private players are expected to invest and become stakeholders, gaining the rights to sell produced radioisotopes. This collaboration aims to accelerate production and distribution while encouraging innovation in the nuclear medicine sector.
**Current Supply Scenario and Challenges**
At present, India lacks a dedicated reactor exclusively for isotope production. Existing nuclear reactors used in medical treatments also conduct physics and radiation experiments, which limits their capacity to focus on isotope generation.
BARC currently supplies approximately two lakh units of nuclear materials annually to medical institutions nationwide for diagnostics and treatment of diseases such as cancer. Major hospitals like Tata Memorial Centre handle about 10% of the total patient load, while around 370 other hospitals collectively manage nearly 60%.
**Reducing Dependence on Imports**
The new reactor is expected to significantly reduce India’s dependence on imported radioisotopes from Europe, Australia, and other Asian countries. Achieving self-sufficiency in isotope production will not only lower treatment costs but also strengthen India’s position as a key player in the global nuclear medicine market.
Radioisotopes produced by the reactor have wide-ranging applications, from medical imaging and cancer treatment to various industrial uses, such as detecting flow malfunctions and ensuring process efficiency.
With this new infrastructure, India moves closer to providing affordable, accessible cancer treatment while expanding its footprint in the rapidly growing nuclear medicine industry.
https://www.newsbytesapp.com/news/india/india-to-get-dedicated-nuclear-reactor-for-cancer-treatment/story
［熊本県］医療過誤の医師に禁錮1年6月求刑 熊本地裁
—
title: 熊本地裁、医療過誤の医師に禁錮1年6月の求刑
date: 2025-10-11 06:00
categories: [熊本, 社会, 医療]
—
熊本地裁は、北九州市の済生会八幡総合病院で発生した医療過誤に関し、投薬ミスを犯した医師に対して禁錮1年6月の求刑を行いました。
事件は、90代の患者に対し、適正濃度の16.7倍の薬剤が投与されたことに端を発しています。誤投与された薬は約4時間40分後に患者の死亡を招いたとされています。
今回の裁判は医療現場における安全管理の重要性を改めて問うものとなっており、関係者や市民から強い関心が寄せられています。
※この記事は有料会員限定です。7日間の無料トライアルがあり、1日37円で読み放題となっています。
西日本新聞meにて詳細をお読みいただけます。
【関連記事】
– 熊本地裁の医療過誤事件一覧
– 投薬ミス防止に向けた取り組み
—
[西日本新聞meとは](#) | 有料会員限定記事 | クリップ機能は有料会員のみご利用可能です。
https://www.nishinippon.co.jp/item/1410153/
たん検査、肺がん検診から除外 喫煙率低下で効果小さく
医療・健康
たん検査、肺がん検診から除外
喫煙率低下で効果小さく
2025年10月10日 18:19（更新 18:21）
［有料会員限定記事］
—
肺がん検診において、50歳以上のたばこを多く吸う人を対象に胸部エックス線検査と併用されている「たんの検査」について、厚生労働省の有識者検討会は10日、検査の効果が小さくなっているとして、2025年以降、肺がん検診から除外する方針を示しました。
これは近年の喫煙率の低下により、たん検査によって得られる効果や検診の有効性が減少しているためです。
詳細な記事は有料会員限定となっています。
—
※クリップ機能は有料会員の方のみご利用いただけます。
※西日本新聞meとは？
7日間無料トライアル、1日37円で読み放題。年払いならさらにお得です。
https://www.nishinippon.co.jp/item/1409954/
Father of the deceased patient attacks government doctor in hospital
A government doctor was seriously injured after being attacked with a machete by a man at the taluk hospital in Thamarassery, Kerala, in Kozhikode district on Wednesday, police said.
The assailant, who is the father of a young girl who recently died of amoebic meningitis, has been taken into custody following the afternoon incident, Kerala Police further informed.
The doctor, identified as Vipin, was struck on the head and has been rushed to a private hospital for treatment, police added.
*This story has been sourced from a third-party syndicated feed/agency. Mid-day accepts no responsibility or liability for the dependability, trustworthiness, reliability, and data of the text. Mid-day management and mid-day.com reserve the sole right to alter, delete, or remove (without notice) the content at their absolute discretion for any reason whatsoever.*
Help us improve further by providing more detailed feedback and stand a chance to win a 3-month e-paper subscription!
https://www.mid-day.com/news/india-news/article/father-of-the-deceased-patient-attacks-government-doctor-in-hospital-23597799
AstraZeneca gets nod to market cancer drug in India
AstraZeneca Pharma announced on Tuesday that it has received approval from the national drug regulator to market a new cancer treatment drug in India.
The company has been granted approval by the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan for an additional indication in the country, according to an official statement.
With this approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours. These patients must have received prior systemic therapy and have no satisfactory alternative treatment options.
This approval marks the first and only antibody-drug conjugate in India with a tumour-agnostic indication, representing a significant advancement in precision oncology, AstraZeneca said.
*Disclaimer:*
This story has been sourced from a third-party syndicated feed/ agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability, and accuracy of the text. Mid-day management and mid-day.com reserve the sole right to alter, delete, or remove (without notice) the content at their absolute discretion for any reason whatsoever.
Help us improve further by providing more detailed feedback and stand a chance to win a 3-month e-paper subscription!
https://www.mid-day.com/news/india-news/article/astrazeneca-gets-nod-to-market-cancer-drug-in-india-23597685
Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data
Dyne Therapeutics Inc. (NASDAQ: DYN) stands out as one of the best stocks to buy under $20.
On September 29, Dyne Therapeutics announced a significant milestone: Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation for its investigational therapeutic, DYNE-251.
This designation targets individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to treatment with DYNE-251.
The Orphan Drug status is a crucial step in the development of DYNE-251, potentially providing benefits such as market exclusivity and regulatory assistance, which can accelerate the availability of this promising therapy for patients in need.
Investors and stakeholders will be closely watching Dyne Therapeutics as it advances its pipeline and seeks to address unmet medical needs in the muscular dystrophy community.
https://ca.finance.yahoo.com/news/dyne-investigational-dmd-drug-dyne-205457972.html